The global musculoskeletal (MSK) disease management market size was valued at USD 4.92 billion in 2024 and is expected to reach USD 25.44 billion by 2032, at a CAGR of 22.80% during the forecast period
The market growth is largely fueled by the increasing prevalence of musculoskeletal disorders, aging populations, and rising awareness about early diagnosis and effective disease management. Technological advancements in treatment options, including minimally invasive procedures, regenerative therapies, and digital health monitoring tools, are further driving market expansion
Furthermore, growing demand from hospitals, rehabilitation centers, and orthopedic clinics for comprehensive MSK disease management solutions is establishing these therapies and services as essential components of patient care. These converging factors are accelerating the adoption of advanced Musculoskeletal (MSK) Disease Management solutions, thereby significantly boosting the growth of the market across diagnostic, therapeutic, and rehabilitation applications